HIV Detail Information

Bictegravir (ID: DG00325) Resistance Data of HIV
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.S24G+p.D25E+p.S39C+p.I60IM+p.L63I+p.T97A+p.L101I+p.S119SR+p.T124N+p.T125A+p.I135V+p.E138T+p.G140S+p.Q148H+p.M154I+p.V165I+p.V201I+p.V259VI
Missense mutation 100 High-level resistance [1]
Resistant Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q164H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.D6T+p.K7E+p.S17N+p.V54I+p.I72V+p.L74M+p.V79I+p.T97A+p.L101I+p.I113L+p.S119R+p.T122I+p.T124N+p.T125A+p.E138K+p.G140A+p.I141AT+p.S147SG+p.Q148R+p.K156N+p.I203M+p.I208M+p.L234V+p.D253E
Missense mutation 100 High-level resistance [1]
Resistant Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q165H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.E69ED+p.E138K+p.G140S+p.Q148H+p.M154I+p.N155H+p.V201I
Missense mutation 100 High-level resistance [1]
Resistant Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q166H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E138K+p.G140A+p.Q148R
Missense mutation 18 Low-level resistance [2]
Resistant Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, G140A, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.E138K+p.Q148K
Missense mutation 54 Intermediate resistance [2]
Resistant Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, E138K, Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Resistant Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.Q148K+p.D232N
Missense mutation 28 Low-level resistance [3]
Resistant Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E226Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Drug Sensitivity Data Categorized by Their Corresponding Mechanisms
       Aberration of the Drug's Therapeutic Target (ADTT) Click to Show/Hide
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.M50L+p.I72V+p.Q95QH+p.T112V+p.I113V+p.T124A+p.T125A+p.G134D+p.V201I+p.Q221QKR+p.L234I+p.D256E
Missense mutation 1.1 Susceptible [4]
p.I5V+p.S17N+p.M50L+p.E69G+p.I72V+p.T112I+p.I113V+p.T124A+p.T125A+p.T174A+p.V201I+p.T218I+p.L234I+p.D256E
Missense mutation 0.3 Susceptible [4]
p.K42Q+p.L101I+p.T112V+p.T124A+p.T125A+p.K136Q+p.G163R+p.V201I+p.L234I+p.R269K+p.D278A+p.S283G
Missense mutation 0.2 Susceptible [4]
p.K14R+p.V31I+p.I72V+p.T112V+p.I113V+p.T124A+p.T125A+p.G134N+p.I135V+p.D167E+p.V201I+p.T206S+p.I208L+p.N222K+p.L234I+p.A265V+p.R269K+p.S283G
Missense mutation 1.5 Susceptible [4]
p.K14R+p.V31I+p.L74I+p.L101I+p.T112V+p.T124A+p.T125A+p.G134N+p.I135V+p.K136T+p.H171Q+p.V201I+p.T206S+p.I208M+p.T218I+p.L234I+p.A265V+p.R269K+p.D286N
Missense mutation 0.1 Susceptible [4]
p.L101I+p.T122I+p.T124N+p.A265V
Missense mutation 1.2 Susceptible [4]
p.S17N+p.I72V+p.I84V+p.T124A+p.M154I+p.K173R
Missense mutation 0.9 Susceptible [4]
p.S17N+p.L28I+p.P30A+p.I84L+p.S119T+p.T124A+p.K136Q+p.V165I+p.I200T+p.V201I+p.K211R+p.T218I+p.L234V+p.D256E+p.S283G
Missense mutation 1.2 Susceptible [4]
p.L101I+p.T125A+p.I135V+p.D167DE+p.G193R+p.V201I+p.I208L+p.K211T+p.A265V+p.S283G
Missense mutation 1 Susceptible [4]
p.E11D+p.D25E+p.V31I+p.F100Y+p.L101I+p.T112V+p.S119P+p.K136Q+p.V201I+p.T218I+p.L234I+p.A265V+p.R269K+p.D278A+p.S283G
Missense mutation 1.2 Susceptible [4]
p.K14R+p.A21T+p.A23V+p.S39N+p.I72V+p.T112V+p.T124A+p.T125A+p.G134N+p.I135V+p.K136R+p.D167E+p.V201I+p.L234I+p.S283G
Missense mutation 0.5 Susceptible [4]
p.K14R+p.A21T+p.V31I+p.V32I+p.M50I+p.I72V+p.T112V+p.T124A+p.T125A+p.G134N+p.I135V+p.K136R+p.D167E+p.V201I+p.T206S+p.L234I+p.S283G
Missense mutation 0.2 Susceptible [4]
p.V88I+p.M154I
Missense mutation 0.4 Susceptible [4]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model MT-2 cells Umbilical cord blood Homo sapiens (Human) CVCL_2631
MT-4 cells Umbilical cord blood Homo sapiens (Human) CVCL_2632
Experiment for
Molecule Alteration		 PCR; DNA sequencing assay
Experiment for
Drug Resistance		 PhenoSense assay
Mechanism Description Amino acid changes in IN may contribute to bictegravir resistance or sensitivity.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.S39R+p.L45V+p.M50ML+p.T66A+p.V75I+p.L101I+p.T124A+p.K127R+p.S147SG+p.G163K+p.V201I
Missense mutation 0.2 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q148H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.S24H+p.V31I+p.L68I+p.I73V+p.E92Q+p.L101I+p.T112V+p.S119T+p.T124G+p.T125A+p.G134N+p.K136T+p.V165I+p.V201I+p.T206S+p.L234I+p.D256E+p.S283G
Missense mutation 0.4 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q149H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.A23T+p.S24G+p.D25E+p.L28I+p.I72V+p.T124A+p.Q148R+p.V165I+p.L172LF+p.H183HP+p.Q209QP+p.A239AT
Missense mutation 0.8 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q150H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.R20K+p.M50I+p.V77A+p.L101I+p.T112I+p.T124A+p.T125A+p.K136Q+p.G193E+p.V201I+p.T206S+p.T218L+p.I220V+p.L234V+p.D256E+p.R263K+p.D279G+p.S283G
Missense mutation 1.1 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q151H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.R20K+p.E92Q+p.V201I+p.K211R+p.S230SN+p.D232E+p.D256E
Missense mutation 1.4 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q152H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.V31I+p.T97A+p.L101I+p.T112V+p.S119R+p.T124A+p.T125S+p.G134N+p.K136T+p.N155H+p.V165I+p.V201I+p.T206S+p.Y227F+p.L234I+p.S255N+p.D256E+p.S283G
Missense mutation 1.5 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q153H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.M154L+p.N155H+p.V201I+p.D232N+p.L242LF
Missense mutation 1.7 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q154H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.S17T+p.S39N+p.I72V+p.S119P+p.T122I+p.T124N+p.T125A+p.V151I+p.N155H+p.N222K+p.P261A
Missense mutation 1.7 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q155H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.L101V+p.T112I+p.T125V+p.N155H+p.E157Q+p.K160Q+p.G193E+p.S230N+p.L234I+p.A265V+p.D279G
Missense mutation 1.8 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q156H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K7KR+p.S17N+p.I72V+p.I84L+p.T97A+p.L101I+p.T112I+p.S119P+p.T122I+p.T124N+p.T125A+p.K136Q+p.Y143R+p.V201I+p.A205S+p.K211R+p.T218L+p.L234V+p.D256E+p.I268L+p.D270H
Missense mutation 2.4 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q157H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.K14R+p.V31I+p.V32I+p.L45Q+p.L101I+p.T112V+p.T125A+p.G134N+p.I135V+p.K136T+p.Y143C+p.V201I+p.T206S+p.S230R+p.L234I+p.N254NS+p.R269K+p.D270H
Missense mutation 2.5 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q158H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S17N+p.D25E+p.S119G+p.T122I+p.T124N+p.T125A+p.M154I+p.N155H+p.K156R+p.T206S+p.T218S
Missense mutation 2.5 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q159H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G59D+p.I60V+p.E138K+p.Q148R+p.K173R+p.T218S+p.S230N+p.M275S+p.C280S
Missense mutation 3.2 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q160H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.V31I+p.G70R+p.I84V+p.L101I+p.S119P+p.T122I+p.N155H+p.G163E+p.V201I+p.D256E
Missense mutation 3.4 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q161H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.S17C+p.L68V+p.L101I+p.T124N+p.T125A+p.I135V+p.G140A+p.Q148R+p.D253E+p.V281M
Missense mutation 5.4 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q162H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E11D+p.K14R+p.S17T+p.V31I+p.L45V+p.A91S+p.L101I+p.T124A+p.E138Q+p.G140C+p.Q148R+p.V151I+p.K219N+p.N222K+p.L234I+p.V259I
Missense mutation 8 Susceptible [1]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
In Vitro Model TZM-bl cells Uterus Homo sapiens (Human) CVCL_B478
Experiment for
Molecule Alteration		 Population sequencing of the integrase region assay
Experiment for
Drug Resistance		 TZM-bl cell line-based phenotypic assay
Mechanism Description In this study, DTG, BIC, and CAB demonstrated a comparable activity on a panel of INSTI-resistant strains isolated from patients exposed to RAL, EVG, and/or DTG, with a significantly reduced susceptibility only with the pathway Q163H/k/R plus one to two additional INSTI mutations.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.A91E
Missense mutation 0.7 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included A91E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E138K+p.Q148K
Missense mutation 4.4 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E138K+p.Q148R
Missense mutation 1.6 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E138K
Missense mutation 0.8 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E138K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E157K
Missense mutation 1 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E157K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E92Q+p.G140A
Missense mutation 1.4 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q, G140A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E92Q
Missense mutation 1.1 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included E92Q.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G118R
Missense mutation 3.4 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G118R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G140A+p.Q148R
Missense mutation 2.3 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140A, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G140A
Missense mutation 0.6 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G140E
Missense mutation 1.1 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G140E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G70R
Missense mutation 0.9 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included G70R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72A+p.N155H
Missense mutation 1 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72A, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.I72A
Missense mutation 0.7 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included I72A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L234F
Missense mutation 1.2 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L234F.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L45Q+p.T115H
Missense mutation 1.5 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L45Q, T115H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74I+p.T97A
Missense mutation 0.6 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74I, T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74I
Missense mutation 0.9 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.S119P
Missense mutation 0.6 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, S119P.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.S119R
Missense mutation 0.8 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.T97A+p.S119G
Missense mutation 0.4 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.T97A+p.S119P
Missense mutation 0.5 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119P.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.T97A+p.S119R
Missense mutation 0.6 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.T97A+p.S119T
Missense mutation 0.5 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A, S119T.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M+p.T97A
Missense mutation 0.5 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included L74M, T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50I+p.T97A
Missense mutation 0.6 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included M50I, T97A.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.N155H
Missense mutation 1.2 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.NULL
Missense mutation 1 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included NULL.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q148K
Missense mutation 0.9 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q148R+p.N155H
Missense mutation 2.1 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148R, N155H.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.Q148R
Missense mutation 0.6 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.R263K
Missense mutation 1.6 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119R+p.F121Y
Missense mutation 0.7 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S119R, F121Y.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S147G
Missense mutation 1.1 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S147G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S153F
Missense mutation 1.4 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153F.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S153Y+p.L234F
Missense mutation 2.2 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153Y, L234F.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S153Y
Missense mutation 2 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S153Y.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S24G+p.N155H+p.D253E
Missense mutation 1.4 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included S24G, N155H, D253E.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T122I
Missense mutation 1 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T122I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.E138K+p.Q148R
Missense mutation 3.7 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, E138K, Q148R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.Q148K
Missense mutation 2.1 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, Q148K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.R263K
Missense mutation 1.5 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, R263K.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I+p.S153F
Missense mutation 0.6 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I, S153F.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T66I
Missense mutation 0.4 Susceptible [2]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T66I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.G118R+p.S119R
Missense mutation 0.5 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, G118R, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.G118R
Missense mutation 2.8 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, G118R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.G163R
Missense mutation 1 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, G163R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.S119G
Missense mutation 0.3 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119G.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.S119P
Missense mutation 0.5 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119P.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.S119R
Missense mutation 0.7 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119R.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A+p.S119T
Missense mutation 0.4 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97A, S119T.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97I
Missense mutation 0.5 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97I.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97S
Missense mutation 0.8 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97S.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97V
Missense mutation 0.4 Susceptible [5]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Discovered Using In-vivo Testing Model
Experiment for
Molecule Alteration		 Sanger sequencing assay; GeneSeq assay; Population sequencing of the integrase region assay; DNA sequencing assay; Site-directed mutagenesis
Experiment for
Drug Resistance		 PhenoSense assay; Viral load assay; A single-cycle assay; TZM-bl cell line-based phenotypic assay; SDMs and phenotyping assay
Mechanism Description Some mutations identified were assiacted with resistance in the HIV isolates, those mutations included T97V.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.P145S+p.D232N
Missense mutation 0.2 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E157Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.3 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E158Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146P+p.D232N
Missense mutation 0.3 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E159Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.M50I+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.3 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E160Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66I+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.3 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E161Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66I+p.I72V+p.S123G+p.T124A+p.K127R+p.E157Q+p.D232N
Missense mutation 0.3 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E162Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.F121Y
Missense mutation 0.4 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E163Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66A+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.4 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E164Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140C+p.D232N
Missense mutation 0.4 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E165Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72A+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.5 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E166Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72N+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.5 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E167Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.T97A
Missense mutation 0.6 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E168Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.L68I+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.6 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E169Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140A+p.D232N
Missense mutation 0.6 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E170Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.L74M
Missense mutation 0.7 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E171Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148H+p.D232N
Missense mutation 0.7 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E172Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N
Missense mutation 0.7 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E173Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.L68V+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.7 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E174Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72T+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.7 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E175Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E138A+p.D232N
Missense mutation 0.7 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E176Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.V151A+p.D232N
Missense mutation 0.7 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E177Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.M50I+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N
Missense mutation 0.7 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E178Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119G
Missense mutation 0.8 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E179Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E138K+p.D232N
Missense mutation 0.8 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E180Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.D232N
Missense mutation 0.8 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E181Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119P
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E182Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119T
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E183Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Y143C+p.D232N
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E184Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Y143H+p.D232N
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E185Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148K+p.D232N
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E186Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.Q95K+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E187Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146K+p.D232N
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E188Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.V151L+p.D232N
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E189Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G163K+p.D232N
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E190Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E170A+p.D232N
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E191Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.M50I+p.I72V+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E192Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q148R+p.E157Q+p.D232N
Missense mutation 0.9 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E193Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.M50I
Missense mutation 1 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E194Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N
Missense mutation 1 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E195Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.Q95R+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E196Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.A128T+p.D232N
Missense mutation 1 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E197Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S153A+p.D232N
Missense mutation 1 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E198Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.S147G+p.D232N
Missense mutation 1 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E199Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.Q148R+p.D232N
Missense mutation 1 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E200Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.S119R
Missense mutation 1.1 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E201Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.G163R
Missense mutation 1.1 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E202Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.H51Y+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.1 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E203Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.M50I+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.1 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E204Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.2 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E205Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E157Q+p.D232N
Missense mutation 1.2 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E206Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S119P+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N
Missense mutation 1.2 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E207Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.E92G+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.3 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E208Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Y143R+p.D232N
Missense mutation 1.3 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E209Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N
Missense mutation 1.3 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E210Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146R+p.D232N
Missense mutation 1.3 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E211Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.E92Q+p.S123G+p.T124A+p.K127R+p.E157Q+p.D232N
Missense mutation 1.3 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E212Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S147G+p.E157Q+p.D232N
Missense mutation 1.3 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E213Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.T66K+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.4 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E214Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146L+p.D232N
Missense mutation 1.4 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E215Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.E157K+p.D232N
Missense mutation 1.4 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E216Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.E92Q+p.S119P+p.S123G+p.T124A+p.K127R+p.D232N
Missense mutation 1.4 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E217Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.M50I+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.D232N
Missense mutation 1.4 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E218Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S153F+p.D232N
Missense mutation 1.5 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E219Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.S153Y+p.D232N
Missense mutation 1.6 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E220Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.N155H+p.E157Q+p.D232N
Missense mutation 1.6 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E221Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.D232N+p.R263K
Missense mutation 1.7 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E222Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.Q148R+p.D232N
Missense mutation 2 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E223Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.G140S+p.Q148H+p.D232N
Missense mutation 2.2 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E224Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
Key Molecule: HIV1 Integrase (HIV1 IT)
 Molecule Info 
Sensitive Disease Human immunodeficiency virus infection [ICD-11: 1C62.0]
Molecule Alteration
Alteration Patterns Alteration Types Resistance Mutation Total Point Scores Levels of Drug resistance base on the total point score Ref
p.E10D+p.I72V+p.S123G+p.T124A+p.K127R+p.Q146I+p.D232N
Missense mutation 2.3 Susceptible [3]
Sensitive Drug Bictegravir
 Drug Info 
Experimental Note Identified from the Human Clinical Data
Experiment for
Molecule Alteration		 IN sequencing assay
Experiment for
Drug Resistance		 SDMs and phenotyping assay
Mechanism Description Total 6 of 39 minor INSTI-R mutations (M50I, S119P/G/T/R, and E157Q) were found in >1% of IN-treatment-na ve subjects with no impact on INSTI susceptibility. When each combined with major INSTI-R mutation, M50I, S119P, and E225Q led to decreased susceptibility to elvitegravir but remained sensitive to dolutegravir and bictegravir.
References
Ref 1 Comparable In Vitro Activities of Second-Generation HIV-1 Integrase Strand Transfer Inhibitors (INSTIs) on HIV-1 Clinical Isolates with INSTI Resistance Mutations. Antimicrob Agents Chemother. 2019 Dec 20;64(1):e01717-19. doi: 10.1128/AAC.01717-19. Print 2019 Dec 20.
Ref 2 Integrase Inhibitor Resistance Selections Initiated with Drug Resistant HIV-1.
Ref 3 Antiviral activity of HIV-1 integrase strand-transfer inhibitors against mutants with integrase resistance-associated mutations and their frequency in treatment-na ve individuals. J Med Virol. 2019 Dec;91(12):2188-2194. doi: 10.1002/jmv.25564. Epub 2019 Aug 20.
Ref 4 Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile. Antimicrob Agents Chemother. 2016 Nov 21;60(12):7086-7097. doi: 10.1128/AAC.01474-16. Print 2016 Dec.
Ref 5 Bictegravir Resistance Profile: Data for External Experts.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.